EGFR and skin squamous cell carcinoma: Anti-PD-1 antibodies such as cemiplimab-rwlc appear to achieve higher response rates than do EGFR inhibitors and chemotherapy, and in 2018, cemiplimab-rwlc was approved by the US Food and Drug Administration (FDA) as the first medication for advanced cSCC.